Skip to main content
Digital Seminar

Psychedelic-Assisted Psychotherapies: A Policy Perspective

Victor Cabral, MSW, LSW, CCTP-I
1 Hour 02 Minutes
Audio and Video
Jul 28, 2022
Product Code:
Media Type:
Digital Seminar
Never expires.


In anticipation of FDA approval and medicalization, many clinicians have jumped at the opportunity to be trained in these modalities and others are interested in learning more, but many questions remain unanswered around the current policy landscape, changes needed to welcome these medicines into our current healthcare system and in psychotherapy. This goal of this session is to provide clinicians with an overview of the history and current state of psychedelic policy and the implications for clinicians interested in practicing psychedelic-assisted therapy. 


Planning Committee Disclosure - No relevant relationships All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners.  For speaker disclosures, please see the faculty biography.


PESI Australia, in collaboration with PESI in the USA, offers quality online continuing professional development events from the leaders in the field at a standard recognized by professional associations including psychology, social work, occupational therapy, alcohol and drug professionals, counselling and psychotherapy. On completion of the training, a Professional Development Certificate is issued after the individual has answered and submitted a quiz and course evaluation. This program is worth 1.25 hours CPD for points calculation by your association.



Victor Cabral, MSW, LSW, CCTP-I's Profile

Victor Cabral, MSW, LSW, CCTP-I Related seminars and products

Victor Cabral, MSW, LSW, CCTP-I, (He/Him/His) is a collaborative and strategic leader who is making an impact on historical inequalities in his community and across the United States. Victor is the Founder of Dreamers of the Day, LLC, and serves as the Director of Policy and Regulatory Affairs for Fluence International Inc., a company that provides evidence-based training in psychedelic therapy and integration services to clinicians across the globe. Before joining Fluence, Victor served as Deputy Director for the Pennsylvania Governor’s Office of Advocacy and Reform where he co-led the implementation of the Trauma-Informed PA Plan, helped establish the first Racial Day of Healing in Pennsylvania history, and developed free trauma trainings for Pennsylvanians in collaboration with BIPOC mental health and trauma, and psychedelic medicine. He is a Licensed Social Worker and practicing psychotherapist in Pennsylvania with training in Internal Family Systems, Psychedelic-Assisted Psychotherapy and Psychedelic Integration.

Speaker Disclosures:
Financial: Victor Cabral is the Director of Policy and Regulatory Affairs at Fluence. He receives a speaking honorarium from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Victor Cabral is the Justice, Equity, Diversity, and Inclusion Co-Chair for the American Psychedelic Practitioners Association.



  1. Develop understanding of a brief history of psychedelic drug policy. 
  2. Analyze the FDA approval process and breakthrough designation and DEA scheduling. 
  3. Differentiate the various phases in the process of approval and where MDMA, Psilocybin, and Ketamine presently fall in this process.
  4. Formulate comprehension of the main policy issues currently facing the field of psychedelic-assisted therapy. 
  5. Debate the implications for practice and identify at least 1 way they can support the successful adoption of these new therapies.


  • History of Psychedelic Drug Policy 
  • FDA approval process, breakthrough designation, and DEA scheduling 
  • Psychedelic medicines currently being studied and/or used in therapy 
  • Main policy issues in the field of psychedelics 
  • Implications for practice and ways to be involved as clinicians

Target Audience

  • Counsellors
  • Marriage & Family Therapists
  • Nurses
  • Nurse Practitioners
  • Physicians
  • Psychologists
  • Social Workers
  • Other Behavioral Health Professionals

Please wait ...

Back to Top